| abstract |
[PROBLEMS] In valsartan, which is difficult to formulate and the size of each dosage form is large in the conventional method, A solid oral preparation having a smaller dosage form than before is obtained. A) an active ingredient selected from valsartan and optionally HCTZ, and b) relates to solid oral dosage forms containing pharmaceutically acceptable additives suitable for the production of solid oral dosage forms by the compression method. [Selection figure] None |